KR20240153565A - Crf2 수용체 작용제 및 치료법에서의 이의 용도 - Google Patents

Crf2 수용체 작용제 및 치료법에서의 이의 용도 Download PDF

Info

Publication number
KR20240153565A
KR20240153565A KR1020247028787A KR20247028787A KR20240153565A KR 20240153565 A KR20240153565 A KR 20240153565A KR 1020247028787 A KR1020247028787 A KR 1020247028787A KR 20247028787 A KR20247028787 A KR 20247028787A KR 20240153565 A KR20240153565 A KR 20240153565A
Authority
KR
South Korea
Prior art keywords
acid
gglu
cooh
amino
valine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247028787A
Other languages
English (en)
Korean (ko)
Inventor
필리프 자니악
마리-로랑 오주웍스
다니엘라 로베르시
엘리자베타 비앙키
마르티나 트리페피
알레시아 산토프레테
Original Assignee
코르테리아 파마슈티컬스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 코르테리아 파마슈티컬스 filed Critical 코르테리아 파마슈티컬스
Publication of KR20240153565A publication Critical patent/KR20240153565A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
KR1020247028787A 2022-02-23 2023-02-21 Crf2 수용체 작용제 및 치료법에서의 이의 용도 Pending KR20240153565A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22158188.7A EP4234574A1 (en) 2022-02-23 2022-02-23 Crf2 receptor agonists and their use in therapy
EP22158188.7 2022-02-23
PCT/EP2023/054317 WO2023161229A1 (en) 2022-02-23 2023-02-21 Crf2 receptor agonists and their use in therapy

Publications (1)

Publication Number Publication Date
KR20240153565A true KR20240153565A (ko) 2024-10-23

Family

ID=80819682

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247028787A Pending KR20240153565A (ko) 2022-02-23 2023-02-21 Crf2 수용체 작용제 및 치료법에서의 이의 용도

Country Status (15)

Country Link
US (1) US20260001928A1 (https=)
EP (2) EP4234574A1 (https=)
JP (1) JP2025508820A (https=)
KR (1) KR20240153565A (https=)
CN (1) CN118843638A (https=)
AU (1) AU2023224327A1 (https=)
CA (1) CA3247142A1 (https=)
ES (1) ES3063881T3 (https=)
HR (1) HRP20260115T1 (https=)
IL (1) IL314055A (https=)
IS (1) IS050770A (https=)
MX (1) MX2024010296A (https=)
PL (1) PL4482578T3 (https=)
WO (1) WO2023161229A1 (https=)
ZA (1) ZA202406196B (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025104264A1 (en) * 2023-11-17 2025-05-22 Gubra A/S Hcrhr2 selective polypeptides
WO2026064495A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof
WO2026064486A1 (en) * 2024-09-20 2026-03-26 Neurocrine Biosciences, Inc. Chemically modified peptides and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008047241A2 (en) * 2006-10-16 2008-04-24 Conjuchem Biotechnologies Inc. Modified corticotropin releasing factor peptides and uses thereof
JOP20170153A1 (ar) 2016-07-15 2019-01-30 Lilly Co Eli نظائر urocortin-2 جديدة معدلة بحمض دهني لعلاج داء السكري وأمراض الكلى المزمنة
WO2019140030A1 (en) * 2018-01-12 2019-07-18 Eli Lilly And Company Combination therapy
US20250243255A1 (en) * 2020-08-19 2025-07-31 Sanofi Crf2 receptor agonists and their use in therapy

Also Published As

Publication number Publication date
IS050770A (is) 2024-10-15
CN118843638A (zh) 2024-10-25
ZA202406196B (en) 2025-03-26
EP4482578C0 (en) 2025-12-24
ES3063881T3 (en) 2026-04-21
EP4482578B1 (en) 2025-12-24
EP4482578A1 (en) 2025-01-01
IL314055A (en) 2024-09-01
HRP20260115T1 (hr) 2026-03-13
EP4234574A1 (en) 2023-08-30
JP2025508820A (ja) 2025-04-10
MX2024010296A (es) 2024-09-18
US20260001928A1 (en) 2026-01-01
WO2023161229A1 (en) 2023-08-31
AU2023224327A1 (en) 2024-08-29
PL4482578T3 (pl) 2026-03-16
CA3247142A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
KR102440323B1 (ko) 인크레틴 유사체 및 그의 용도
CN111491658B (zh) 肠促胰岛素类似物及其用途
JP7832927B2 (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
JP7250814B2 (ja) 新規ｇｌｐ－１類似体
EP4482578B1 (en) Crf2 receptor agonists and their use in therapy
KR102755938B1 (ko) 변형된 지질화된 릴랙신 b 사슬 펩타이드 및 이들의 치료적 용도
CN102596228A (zh) 神经肽-2受体(y-2r)激动剂
WO2024163535A1 (en) Gip/glp1/gcg tri-receptor agonists and uses thereof
CA2606894A1 (en) Novel compounds as glp-i agonists
HK40112064A (zh) Crf2受体激动剂及其在治疗中的用途
HK40095414A (en) Crf2 receptor agonists and their use in therapy
RU2845766C1 (ru) Агонисты рецептора crf2 и их применение в терапии
JP2026071260A (ja) Ｃｒｆ２受容体アゴニスト及び治療におけるその使用
HK40087027A (en) Crf2 receptor agonists and their use in therapy
HK40087027B (en) Crf2 receptor agonists and their use in therapy
WO2024213022A1 (zh) 肠促胰素类似物及其制备方法和应用
TW202511281A (zh) 抗病毒多肽類似物
KR20260022948A (ko) Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20240827

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application